MGNX income name for the duration finishing December 31, 2024.
Symbol supply: The Motley Idiot.
MacroGenics (MGNX -2.75%)This fall 2024 Income CallMar 20, 2025, 4:30 p.m. ET
Contents:
Ready Remarks Questions and Solutions Name Individuals
Ready Remarks:
Operator
Excellent afternoon. We can start the MacroGenics fourth quarter and entire 12 months 2024 company development and monetary effects convention name in only a second. All members are in a listen-only mode, and we will be able to habits a query and solution consultation on the conclusion of the decision. At this level, I can flip the decision over to Jim Karrels, senior vice chairman and leader monetary officer of MacroGenics.
Please continue.
James Karrels — Senior Vice President, Leader Monetary Officer, and Secretary
Thanks, operator. Excellent afternoon, and welcome to MacroGenics convention name to speak about our fourth quarter and entire 12 months 2024 monetary and operational effects. For someone who has now not had the danger to check those effects, we’ve issued a press liberate this afternoon outlining nowadays’s bulletins. This liberate is to be had underneath the traders tab on our site at macrogenics.com.
You may additionally hear to this convention name by way of webcast on our site, the place it’s going to be archived for 30 days starting roughly two hours after the decision is done. I would love to alert listeners that nowadays’s dialogue will come with statements in regards to the corporate’s long run expectancies, plans, and possibilities that represent forward-looking statements for functions of the protected harbor provision underneath the Non-public Securities Litigation Reform Act of 1995. Exact effects might range materially from the ones indicated through those forward-looking statements because of more than a few necessary elements, together with the ones mentioned within the possibility elements phase of our annual, quarterly, and present experiences filed with the SEC. As well as, any forward-looking statements constitute our perspectives solely as of nowadays and must now not be relied upon as representing our perspectives as of any next date.
Whilst we might elect to replace those forward-looking statements in the future sooner or later, we in particular disclaim any legal responsibility to take action even though our perspectives alternate excluding to the level required through appropriate legislation. All through nowadays’s name, I can be joined through Dr. Scott Koenig, president and leader government officer of MacroGenics; and Dr. Stephen Eck, our senior vice chairman, scientific construction, and leader scientific officer.
And now, I would like to show the decision over to Scott.
Scott E. Koenig — President, Leader Government Officer, and Director
Thanks, Jim. I would love to welcome everybody collaborating by way of convention name and webcast nowadays. 2024 was once a very powerful 12 months for MacroGenics as we accomplished a number of vital scientific construction milestones and are well-positioned to construct upon that momentum in 2025. We’ve got a various and promising scientific portfolio, and we sit up for a 12 months of persisted development.
On nowadays’s name, we will be able to supply key updates on our trade and scientific methods. I’m going to now flip it over to Stephen to speak about the ones scientific updates.
Stephen Eck — Senior Vice President, Scientific Construction, and Leader Clinical Officer
Thanks, Scott. We made significant developments in 2024 and sit up for persisted execution as we expand and develop our portfolio of antibody-based most cancers therapies in 2025. First, from our proprietary investigational pipeline, I can speak about lorigerlimab, our bispecific tetravalent DART molecule designed to allow blockade of PD-1 and CTLA-4 with doubtlessly enhanced CTLA-4 blockade on T cells co-expressing those immune checkpoint molecules which might be extremely enriched within the tumor microenvironment. I am happy to percentage that enrollment is entire within the ongoing LORIKEET segment 2 trial, a 150-patient randomized be taught for lorigerlimab together with docetaxel as opposed to docetaxel by myself in second-line chemotherapy-naive sufferers with metastatic castration-resistant prostate most cancers.
The present trial design features a number one be taught endpoint of radiographic progression-free survival. For the reason that this endpoint is an event-driven, the provision and next presentation of ultimate rPFS knowledge depends upon the eventual rPFS occasion accrual fee. We watch for offering a scientific replace for LORIKEET in the second one part of this 12 months. According to our cumulative enjoy up to now from our segment 1 and segment 2 research of lorigerlimab, together with in metastatic castration-resistant prostate most cancers, a tumor surroundings traditionally insensitive to checkpoint inhibition, we plan to begin the bounds of segment 2 be taught.
This scientific trial will assessment lorigerlimab monotherapy in sufferers with both platinum-resistant ovarian most cancers, PROC, or clean mobile gynecologic most cancers, CCGC. Each constitute unmet want and traditionally were fairly insensitive to checkpoint inhibitor treatment. The be taught’s number one endpoint is ORR with more than one secondary endpoints to be explored. The corporate anticipates enrolling as much as 40 sufferers with PROC and as much as 20 sufferers with CCGC in LINNET, which is anticipated to begin through mid 2025.
Subsequent, I am very excited to replace you on our rising ADC portfolio. We’ve got 3 antibody drug conjugate molecules, two in scientific construction, one in preclinical research, that every incorporate a singular glycan-linked topoisomerase inhibitor-based payload, which can be advanced through our collaboration spouse, Synaffix, a Lonza corporate. I can now stroll you via those 3 applicants. First is MGC026, which is a Topo 1 inhibitor-based ADC that goals B7-H3, an antigen with vast expression throughout more than one forged tumors and a member of the B7 circle of relatives of molecules excited by immune legislation.
We’re eager about the possibility of MGC026 given the molecule was once built the usage of a clinically lively variable area, additionally contained in vobra duo, in addition to the usage of Synaffix’s Topo 1 inhibitor-linker payload, which has proven doubtlessly awesome preclinical profile in comparison to that of different topoisomerase one inhibitors. MGC026 is lately being evaluated in a segment 1 dose escalation be taught in sufferers with complex forged tumors. We watch for dose growth in chosen indications will begin in 2025. We plan to reveal those indications at a later date.
2d is MGC028, a Topo 1 inhibitor-based ADC that goals ADAM9, a member of the ADAM circle of relatives of multifunctional sort one transmembrane proteins that play a job in tumorigenesis and most cancers development and are over-expressed in more than one cancers akin to pancreatic, gastric, adenocarcinoma of the lung, and squamous-cell lung most cancers, amongst others. As a reminder, we prior to now offered preclinical knowledge appearing anti-tumor task of MGC028 in vivo fashions. Additionally, in a nonhuman primate be taught, MGC028 was once properly tolerated at prime dose ranges with gentle reversible unintended effects and no ocular toxicity, which is incessantly a priority with tubulin inhibitor-based ADCs. The IND for MGC028 was once cleared through the FDA early this 12 months, and the primary affected person was once just lately dosed in a segment 1 be taught in sufferers with complex forged tumors.
And 3rd is MGC030, a preclinical Topo 1 inhibitor-based ADC that goals an undisclosed antigen expressed throughout a number of forged tumors. There are lately no authorized remedies to this goal. We watch for filing an Investigational new drug, or IND, utility for MGC030 in 2026, additional increasing our already deep scientific pipeline. In relation to our T mobile engagers, recall that MGD024 is our next-generation bispecific CD123 through CD3 DART molecule that comprises a CD3 element designed to attenuate cytokine liberate syndrome.
Our segment 1 dose escalation be taught of MGD024 is ongoing in sufferers with CD123-positive relapse or refractory hematologic malignancies, together with acute myeloid leukemia and myelodysplastic syndromes. Gilead has the technique to license MGD024 at predefined determination issues right through the segment 1 be taught. After all, I’m going to replace you on vobramitamab duocarmazine, or vobra duo, which is our ADC designed to ship DNA-alkylating duocarmycin cytotoxic payload to tumors expressing B7-H3. We introduced nowadays effects from the TAMARACK segment 2 be taught of vobra duo in sufferers with mCRPC who have been prior to now handled with one prior androgen receptor axis-targeted treatment.
Find out about members will have won as much as one prior taxane containing routine however no different chemotherapy brokers. Those effects according to a knowledge cutoff of February 21, 2025, confirmed mature median rPFS of 9.5 months for the two.0 mg/kg cohort and 10.0 months for the two.7 mg/kg cohort in sufferers with mCRPC. Protection knowledge from the be taught remained in step with our prior knowledge disclosures. According to our interior evaluate and evaluation of TAMARACK efficacy and protection, up to now, we’ve determined to not pursue additional interior construction of vobra duo and are exploring doable possible choices for partnering this system.
We consider the B7-H3 goal continues to have doable and are happy with the development being made with our selection anti-B7-H3 ADC MGC026. As you’ll see, there are a number of upcoming milestones anticipated throughout our portfolio in 2025. We are eager about the development we made in 2024 to advance our methods and sit up for offering additional updates in 2025. And now, I’m going to flip the decision over to Jim.
James Karrels — Senior Vice President, Leader Monetary Officer, and Secretary
Thanks, Stephen. This afternoon MacroGenics reported monetary effects for the 12 months ended December 31, 2024, which spotlight our monetary place. As described in a liberate this afternoon, MacroGenics general earnings was once $150 million for the 12 months ended December 31, 2024 in comparison to general earnings of $58.7 million for the 12 months ended December 31, 2023. The rise was once essentially because of a internet building up of $85 million in earnings identified from milestones accomplished underneath the Incyte license settlement.
Our earnings for the 12 months ended December 31, 2024 incorporated $118.9 million in earnings from collaborative and different agreements, MARGENZA internet gross sales of $16.4 million, and contract production earnings of $13.1 million. Our analysis and construction bills have been $177.2 million for the 12 months ended December 31, 2024, in comparison to $166.6 million for the 12 months ended December 31, 2023. The rise was once essentially because of higher analysis, construction, production, and scientific prices associated with MGC028, our preclinical ADC pipeline, and lorigerlimab, offset through lowered construction and scientific trial prices associated with our prior to now discontinued initiatives and margetuximab. Our promoting, basic and administrative bills have been $71 million for the 12 months ended December 31, 2024, in comparison to $52.2 million for the 12 months ended December 31, 2023.
The rise was once because of an $8 million modification rate we paid to our former industrial spouse pursuant to the asset sale of MARGENZA to TerSera Therapeutics, which closed within the fourth quarter of 2024, in addition to higher noncash stock-based reimbursement and accumulated severance bills associated with the separation settlement with our leader government officer. All through the 12 months ended December 31, 2024, different source of revenue mirrored a $36.3 million acquire identified on our sale of MARGENZA to TerSera. Our internet loss was once $67 million for the 12 months ended December 31, 2024, in comparison to internet lack of $9.1 million for the 12 months ended December 31, 2023. Our money, money equivalents, and marketable securities stability as of December 31, 2024 was once $201.7 million in comparison to $229.8 million as of December 31, 2023.
After all, in the case of our money runway, we watch for that our money, money equivalents, and marketable securities stability of $201.7 million as of December 31, 2024, plus further projected and expected long run bills from companions, must lengthen our money runway into the second one part of 2026. Our expected investment necessities replicate anticipated expenditures associated with the continued segment two LORIKEET be taught of lorigerlimab and metastatic castration-resistant prostate most cancers, in addition to our different scientific and preclinical research lately ongoing. And now, I can flip the decision again to Scott.
Scott E. Koenig — President, Leader Government Officer, and Director
Thanks, Jim. As I prior to now discussed, 2024 was once a 12 months of sturdy execution and necessary development for MacroGenics. We’re eager about our leading edge and proprietary pipeline of product applicants, together with lorigerlimab, MGCO26 and MGC028. And we sit up for proceeding to advance those applicants and sharing our development with you.
Our construction efforts are complemented through our persisted trade construction center of attention, and we have been more than happy to finish the sale of Mar MARGENZA to TerSera Therapeutics within the fourth quarter. The nondilutive capital from this deal, at the side of a $100 million won from Incyte right through the 12 months, has allowed us to proceed to put money into our scientific pipeline and R&D efforts. Finally, the board continues its diligent seek for my successor, and I stay dedicated to supporting the corporate right through the transition duration. We sit up for giving you updates when to be had.
In ultimate, 2025 appears to be an exhilarating 12 months for MacroGenics as we paintings to advance our pipeline, enlarge our partnerships, and force worth for each sufferers and our shareholders. We might now be at liberty to open the decision for questions. Operator?
Questions & Solutions:
Operator
[Operator instructions] Please stand through for our first query, please. And it comes from the road of Peter Lawson with Barclays. Please continue.
Peter Lawson — Analyst
Nice. Thank you such a lot for taking the questions. At the LINNET be taught, what are the gating elements to beginning? After which, at the B7-H3 Topo 1 ADC, the place are you for the — within the dose growth or — yeah.
Stephen Eck — Senior Vice President, Scientific Construction, and Leader Clinical Officer
Yeah, I am satisfied to respond to that. So, with reference to LINNET, as you understand, the usual of deal with — in later-line ovarian most cancers is relatively low. You normally see the whole reaction charges of 10% to fifteen% with anti-PD-1 experimental treatment surroundings. Some chosen experimental trials of ADCs together with checkpoint inhibitors have demonstrated ORRs out of doors about 30%.
This can be a small be taught, however this can be a well-selected affected person inhabitants, which I believe will be capable to tell us about whether or not we will additional expand in those indications. After which, you had a query in regards to the MGC026 a segment 1 be taught. So, that be taught has enrolled relatively properly. We are more than happy with the development now we have made.
You already know, we are properly right into a really nice dosing vary, and we must be deciding on a dose for additional growth someday later this 12 months.
Peter Lawson — Analyst
Gotcha. Thanks such a lot.
Operator
Thanks. One second for our subsequent query, please. Comes from the road of Jonathan Chang with Leerink Companions. Please continue.
Jonathan Chang — Analyst
Hello, guys. Thank you for taking my questions. First query, are you able to speak about the explanation in the back of creating lorigerlimab in ovarian and clear-cell gynecologic cancers? And moment query, on MGC026, when may just we see preliminary scientific knowledge for that program? Thanks.
Stephen Eck — Senior Vice President, Scientific Construction, and Leader Clinical Officer
Yeah. Hello. That is Stephen. So, I’m going to solution the second one query first.
We most probably would possibly not get to turn you knowledge till the latter part of this 12 months for 026. With reference to lorigerlimab in ovarian most cancers and clear-cell gynecologic cancers, I might take that indication as a result of it is principally untreated space so far as checkpoint inhibitors are involved. The checkpoint inhibitors are lately to be had have now not proven as a lot promise as one would love. We expect our checkpoint inhibitor lorigerlimab differentiates properly as a result of we in particular goal the T cells which might be already within the tumor microenvironment and that co-express each PD-1 and CTLA-4.
And in doing so, in large part however now not utterly, spare the T regulatory cells which might be within the outer edge that give upward push to the vintage toxicities that you simply see with the to be had CTLA-4 inhibitors.
Scott E. Koenig — President, Leader Government Officer, and Director
Jonathan, that is Scott. I’m going to simply upload at the different word. Having a look at open areas for treating aggregate checkpoint molecules, our encouraging knowledge that we have got noticed each in reported past due level castration-resistant prostate most cancers and the continued LORIKEET be taught, which is, as you understand, a sign through which is regarded as a [Inaudible] tumor has now not effectively been handled with checkpoints earlier than, we expect ovarian is every other case right here the place identical mechanisms would possibly be successful at the worth and the unintended effects of the lorigerlimab.
Jonathan Chang — Analyst
Were given it. Thank you for taking the questions.
Operator
Thanks. Our subsequent query is from Tara Bancroft with TD Cowen. Please continue.
Nick Lorusso — TD Cowen — Analyst
Thank you, guys. That is Nick, on for Tara. The primary one for me is, given the rPFS knowledge that you simply guys simply reported for vobra duo, how does this lend a hand explain the trail ahead for MGC026? For instance, do you intend to transport this ahead in pre-chemo or post-chemo sufferers, assuming that mCRPC remains to be a sign of passion? After which, the second one query is, for the LORIKEET knowledge that is coming in the second one part of the 12 months, must we predict to peer any rPFS knowledge from that, or is that this essentially simply going to be ORR? Thank you.
Stephen Eck — Senior Vice President, Scientific Construction, and Leader Clinical Officer
Neatly, we without a doubt will see — I’m going to solution the second one query first, Nick. We without a doubt will see ORR, whether or not we see PFS or now not is event-driven. And so, we simply have to attend and spot how the playing cards fall and the way briefly we development, so I will’t speculate past that. Now, your first query is in regard to 026 and the way that differentiates, 026 is significantly other than of vobra duo, 018.
They’ve a special — a somewhat other linker and an absolutely other payload. So, we expect there is alternative for task past what we noticed with 018. And in addition, it is not likely we will be able to see and thus far have not noticed the — probably the most toxicities we noticed with the vobra duo, maximum significantly the pleural effusions.
Scott E. Koenig — President, Leader Government Officer, and Director
And, Nick, that is Scott. I simply wish to upload, your query alluded to the reality of evaluating that during a prostate surroundings. We’ve got now not determined at this level on 026 on which indications. We’re going to let the scientific knowledge information us, clearly, the aggressive panorama and what we see in prostate and different tumors to make a decision what explicit tumor sorts will prioritize for additional growth.
Nick Lorusso — TD Cowen — Analyst
That is very useful, Thanks very a lot.
Operator
Thanks. Our subsequent query is from the road of Jon Miller with Evercore. Please continue.
Jon Miller — Analyst
Hello, guys. Thank you for taking my query. I will construct at the different Jon query at the LINNET indications. I spotted that you are not together with any of the symptoms the place AstraZeneca is creating their PD-1, CTLA-4 bispecific.
Are you able to talk to any plans you may have in the ones extra historically scorching tumors or puts the place we already know that there is a excellent doable for PD-1, CTLA-4 combos. After which, secondly, talking of combos, if LINNET in point of fact does have a awesome tox profile relative to CTLA-4s, are there puts the place chances are you’ll almost be focused on combos of LINNET with non-IO brokers in the ones indications?
Scott E. Koenig — President, Leader Government Officer, and Director
Jon, thank you such a lot in your query. With reference to the pathway, we’re going to continue. Clearly, we need to prioritize our research and given the open area in ovarian. We figured that this was once a possibility for us to benefit from, however we’ve now not excluded the alternatives for different tumors as properly.
We’re going to see how the lorigerlimab LORIKEET be taught comes out. We’re going to see how the LINNET continue. After which, obviously, we’re without a doubt open to searching at different indications in a well timed means. With reference to combos, you hit the nail at the head.
In truth, through finishing the LORIKEET be taught and now demonstrating that we will mix it with a chemotherapeutic, like docetaxel, which on its own has its personal toxicities, we will be able to have a look at different combos sooner or later as we get the general effects on LORIKEET. Given in particular the mechanisms during which LORIKEET is operating, the power to mix this with different ADCs, TKIs, and different therapeutics is without a doubt deliberate sooner or later.
Jon Miller — Analyst
Thank you such a lot.
Operator
Thanks. Our subsequent query is from Stephen Willey with Stifel. Please continue.
Stephen Willey — Analyst
Yeah. Thank you for taking the query. I suppose within the context of doubtless getting an replace of LORIKEET that possibly does now not come with at rPFS earlier than the top of this 12 months, is there simply the rest that you’ll say? I are aware of it’s in point of fact early at this level, however is there the rest that you’ll say with reference to how the development fee seems to be accruing at this level? Is it consistent with its expectancies? Is it going just a little bit slower than anticipated? I do know the randomization scheme here’s 2-to-1 in prefer of lori. So, simply curious.
Stephen Eck — Senior Vice President, Scientific Construction, and Leader Clinical Officer
Sure. I imply it is a 2-to-1 randomization be taught of a be taught designed for 150 sufferers. We are more than happy with how briefly it enrolled. We began within the later a part of 2023 and closed that enrollment for the top of 2024.
So, the be taught’s absolutely enrolled, and we are simply looking ahead to occasions. I believe it is too early to remark at the occasion fee. You already know, so past that, we simply have to attend and spot. It is simply too early to understand.
Scott E. Koenig — President, Leader Government Officer, and Director
You already know, simply an addition is that we had a large choice of sufferers that have been enrolled early in ’24 as properly. And given what the predicted keep an eye on inhabitants would development, it will now not be unreasonable to assume that having a PFS occasion fee in the second one part of the 12 months is imaginable. However as Stephen commented on, till we succeed in the real numbers, we would possibly not speak about it.
Stephen Willey — Analyst
OK. And I believe possibly the query was once requested. I would possibly have ignored the solution. However may just there be some knowledge that is disclosed right here within the again part of the 12 months from LORIKEET, whether or not that is a reaction fee knowledge level, a PSA level?
Stephen Eck — Senior Vice President, Scientific Construction, and Leader Clinical Officer
Yeah, yeah, that without a doubt may just. We simply do not know. I imply — so it is — there are two elements. One, you do not know how properly the keep an eye on arm plays.
There is a excellent little bit of variability, you understand, docetaxel plays in a scientific surroundings and varies from trial to trial. So, there is that issue. After which, there is — you have got the experimental arm. So, we would like to peer how a lot added receive advantages we’ve if it will come right down to the impact dimension.
And the dimensions — larger the impact dimension, the earlier you to find out.
Stephen Willey — Analyst
OK. I suppose the query is simply whether or not or now not there is disclosable knowledge within the absence of getting that rPFS cause.
Scott E. Koenig — President, Leader Government Officer, and Director
Yeah —
Stephen Eck — Senior Vice President, Scientific Construction, and Leader Clinical Officer
The ORR is one thing we will have a look at.
Stephen Willey — Analyst
OK.
Stephen Eck — Senior Vice President, Scientific Construction, and Leader Clinical Officer
And we might be expecting each brokers may just give a contribution to ORR, so it is advisable see differentiation on ORR by myself. And that’s the reason now not as event-driven.
Stephen Willey — Analyst
After which —
Stephen Eck — Senior Vice President, Scientific Construction, and Leader Clinical Officer
There is — there’s a [Inaudible] of time that it takes to get an ORR infrequently.
Stephen Willey — Analyst
Yep, yep, understood. After which simply at the ADC portfolio, are you able to simply remind us what the best unhazardous dose for 026 was once in pre-clinical primate trials?
Scott E. Koenig — President, Leader Government Officer, and Director
Sure.
Stephen Willey — Analyst
And is there any more or less differential in that dosing threshold between 026 and 028 simply as we attempt to take into consideration the relative TI for every of those goals?
Scott E. Koenig — President, Leader Government Officer, and Director
So, Steve, that is Scott. We accomplished doses of fifty mgs in step with kg within the primate research and didn’t hit a poisonous dose. Simply from at that time, the magnitude of the impact right here have been over 20x in the case of human dosing anticipated in the case of space underneath the curve. So, at this — what was once the second one a part of the query?
Stephen Willey — Analyst
I am simply questioning if that fifty mgs in step with kg is appropriate for each applicants or simply 026?
Scott E. Koenig — President, Leader Government Officer, and Director
Sure, for each, for each.
Stephen Willey — Analyst
OK. Very useful. Thank you for taking the questions.
Operator
Thanks. Our subsequent query is from Silvan Tuerkcan with Electorate. Please continue.
Silvan Tuerkcan — Analyst
Thank you. Thank you for taking my questions. Mine’s at the bi-specific MGD024. You might be nearly one and a part years into the segment 1.
Are you able to supply any longer main points on once we may just see knowledge and when Gilead — I do know you discussed that they have got issues the place they are able to choose in, however are we getting on the subject of the sort of issues? May that be this 12 months or would that be subsequent 12 months? Thanks.
Scott E. Koenig — President, Leader Government Officer, and Director
Neatly, expectantly it’s going to be this 12 months. I imply, we are locked right into a fairly gradual in dose escalation design according to what the FDA expects. And so, we are taking an excessively gradual incremental method to dose escalation and characterizing all the opposed occasions very sparsely. So, this can be a little bit of a gradual going trial in comparison to your conventional segment 1 be taught.
We knew this from the start simply according to the place we began. Began very low doses, and slowly labored our approach up. So, you understand, we are without a doubt getting close to, however we aren’t at MTD but.
Silvan Tuerkcan — Analyst
Nice. Thank you for the colour.
Operator
Thanks. One second for our ultimate query please. It comes from Mayank Mamtani with B. Riley Securities.
Please continue.
Mayank Mamtani — B. Riley Monetary — Analyst
Sure, excellent afternoon, crew. Thank you for taking our questions. Simply briefly at the LORIKEET, can you communicate for your expectancies for the discontinuation fee given the CTLA-4, PD1 enjoy prior to now? And I used to be additionally curious to be told what learnings, if any, from the segment 2 enjoy knowledgeable you prioritizing the LINNET program. Simply sorry if I ignored that previous.
Scott E. Koenig — President, Leader Government Officer, and Director
Yeah, so I believe your first query has to do with the discontinuity — what we predict in the case of discontinuation fee. We expect we’re going to do higher than probably the most prior checkpoint inhibitors just because lorigerlimab could be very well-tolerated in sufferers. We now have had sufferers keep at the lorigerlimab for substantial lengths of time in different research. So, we aren’t expecting that we’re going to have an important dropout from the experimental arm.
That’s the aggregate of lorigerlimab with docetaxel, because of intolerability. Clearly, you’ll have some, However we expect this can be a significantly better tolerated drug than say giving ipilimumab [Inaudible] as an example.
Mayank Mamtani — B. Riley Monetary — Analyst
Yeah. Any learnings from that be taught that contributed to the LINNET program —
Stephen Eck — Senior Vice President, Scientific Construction, and Leader Clinical Officer
Neatly, I imply — I imply, after that, there are very other methods or other schooling. So, the learnings are oblique, basically round what dose you wish to have to make use of and what protection profile we must be expecting. Now the LINNET-study is an open-label noncombination be taught. It is a unmarried agent be taught.
So, it is a more practical be taught in that admire.
Scott E. Koenig — President, Leader Government Officer, and Director
And you understand, that is Scott, the totality of the knowledge which inspired us to enter ovarian most cancers was once now not solely according to our reports in LORIKEET, it was once from the segment 1 growth research in prostate. However I must additionally remind you that within the dose escalation be taught, we have been seeing excellent tolerability. In truth, some of the sufferers that had an goal reaction was once a affected person with a significant carcinoma of the fallopian tube which is largely very similar to ovarian most cancers. So, once more, a lot of these issues in mixture and our reports of stepped forward tolerability of having this mix checkpoint inspire us to hunt different indications like ovarian most cancers.
Mayank Mamtani — B. Riley Monetary — Analyst
Thanks. And only one extra. On MGC028, can you touch upon how some distance alongside you’re within the segment 1 be taught and if there may be any particular tumor sort enrichment you have got began doing already? Thank you for taking that query.
Scott E. Koenig — President, Leader Government Officer, and Director
Yeah, in order that be taught simply were given underway a couple of weeks in the past. You already know, we normally have quite a lot of sufferers covered up. I believe that can move in an excessively expeditious means. It is too early to touch upon that.
With reference to the second one a part of your query, we aren’t preselecting sufferers with admire to the extent of ADAM9 expression. I believe that is what you have been alluding to. We’re going to take a look in a while and spot if there’s a differential impact. However for now, we aren’t pre-selecting.
Stephen Eck — Senior Vice President, Scientific Construction, and Leader Clinical Officer
However, you understand, I simply need say we did restrict it to start with to explicit tumor sorts the place we all know adenine has up-regulation, in particular pancreatic, lung, and cholangiocarcinoma. And we’ve concepts through including different tumor sorts therefore. So, we are hoping that right through the dose escalation, we’re going to see proof of task, in addition to tolerability.
Mayank Mamtani — B. Riley Monetary — Analyst
I am excellent. Thanks.
Operator
[Operator instructions] All proper. As I see no additional questions within the queue, I can conclude Q&A consultation. I can flip it again to Scott Koenig for his ultimate remarks.
Scott E. Koenig — President, Leader Government Officer, and Director
Neatly, thanks. In ultimate, I would love to thank everybody for becoming a member of us in this name and for persisted passion in MacroGenics. A different thanking to our workers for his or her persisted dedication, and we sit up for sharing updates on our development right through long run calls. Have a excellent night time.
Operator
Thanks and this concludes our program. [Operator signoff]
Period: 0 mins
Name members:
James Karrels — Senior Vice President, Leader Monetary Officer, and Secretary
Scott E. Koenig — President, Leader Government Officer, and Director
Stephen Eck — Senior Vice President, Scientific Construction, and Leader Clinical Officer
Jim Karrels — Senior Vice President, Leader Monetary Officer, and Secretary
Scott Koenig — President, Leader Government Officer, and Director
Peter Lawson — Analyst
Jonathan Chang — Analyst
Nick Lorusso — TD Cowen — Analyst
Jon Miller — Analyst
Stephen Willey — Analyst
Steve Willey — Analyst
Silvan Tuerkcan — Analyst
Mayank Mamtani — B. Riley Monetary — Analyst
Extra MGNX research
All income name transcripts
